UA103153C2 - Core-1-положительный микроорганизм или его фракции для активирования клеточного иммунитета - Google Patents

Core-1-положительный микроорганизм или его фракции для активирования клеточного иммунитета

Info

Publication number
UA103153C2
UA103153C2 UAA200905965A UAA200905965A UA103153C2 UA 103153 C2 UA103153 C2 UA 103153C2 UA A200905965 A UAA200905965 A UA A200905965A UA A200905965 A UAA200905965 A UA A200905965A UA 103153 C2 UA103153 C2 UA 103153C2
Authority
UA
Ukraine
Prior art keywords
core
fractions
cellular immunity
positive microorganism
immunity activation
Prior art date
Application number
UAA200905965A
Other languages
English (en)
Russian (ru)
Ukrainian (uk)
Inventor
Стеффен Голетц
Филиппе Ульсемер
Аня Леффлер
Original Assignee
Гликотопе Гмбх
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from EP06090208.7A external-priority patent/EP1920781B1/en
Application filed by Гликотопе Гмбх filed Critical Гликотопе Гмбх
Publication of UA103153C2 publication Critical patent/UA103153C2/ru

Links

Classifications

    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
UAA200905965A 2006-11-10 2007-11-12 Core-1-положительный микроорганизм или его фракции для активирования клеточного иммунитета UA103153C2 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP06090208.7A EP1920781B1 (en) 2006-11-10 2006-11-10 Compositions comprising a core-1 positive microorganism and their use for the treatment or prophylaxis of tumors
PCT/EP2007/009766 WO2008055703A2 (en) 2006-11-10 2007-11-12 Microorganisms or fractions thereof capable of activating cellular immunity against carbohydrates

Publications (1)

Publication Number Publication Date
UA103153C2 true UA103153C2 (ru) 2013-09-25

Family

ID=41421508

Family Applications (1)

Application Number Title Priority Date Filing Date
UAA200905965A UA103153C2 (ru) 2006-11-10 2007-11-12 Core-1-положительный микроорганизм или его фракции для активирования клеточного иммунитета

Country Status (9)

Country Link
CN (1) CN101600454A (es)
CY (1) CY1116319T1 (es)
DK (1) DK1920781T3 (es)
ES (1) ES2533965T3 (es)
HR (1) HRP20150363T1 (es)
PT (1) PT1920781E (es)
RS (1) RS53996B1 (es)
SI (1) SI1920781T1 (es)
UA (1) UA103153C2 (es)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103874428B (zh) * 2011-08-22 2017-06-13 葛莱高托普有限公司 解木聚糖拟杆菌物种微生物
CA2866313C (en) * 2012-03-27 2017-11-28 Abbott Laboratories Methods for modulating cell-mediated immunity using human milk oligosaccharides
CN103320363B (zh) * 2013-07-03 2015-02-18 广州中国科学院先进技术研究所 一种用于分离筛选乳酸菌的培养基、配制方法及应用
CN111323283B (zh) * 2020-04-20 2021-06-25 厦门大学 一种富集n-磷酸化蛋白的方法

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP4904266B2 (ja) * 2004-07-26 2012-03-28 ザ リサーチ ファウンデイション オブ ステイト ユニバーシティー オブ ニューヨーク 抗−ｔｆ−抗原抗体の治療的使用

Also Published As

Publication number Publication date
SI1920781T1 (sl) 2015-07-31
CY1116319T1 (el) 2017-02-08
CN101600454A (zh) 2009-12-09
RS53996B1 (en) 2015-10-30
PT1920781E (pt) 2015-05-18
HRP20150363T1 (hr) 2015-07-31
DK1920781T3 (en) 2015-04-20
ES2533965T3 (es) 2015-04-16

Similar Documents

Publication Publication Date Title
MX2009005004A (es) Microorganismos o fracciones de los mismos capaces de activar inmunidad celular contra carbohidratos.
NL301145I1 (es)
MX2008001652A (es) Copolimeros de poliamonio-polisiloxano.
MX2009006536A (es) Compuestos de heteroaril-heteroarilo como inhibidores de cdk para el tratamiento de cancer, inflamacion e infecciones virales.
WO2006124713A3 (en) 4-biarylyl-1-phenylazetidin-2-ones
TW200738270A (en) Method of treating depression using a TNFα antibody
HK1129277A1 (en) Tannate salt of rasagiline
TW200608961A (en) Methods and reagents for the treatment of metabolic disorders
TW200720693A (en) A comfortable ophthalmic device and methods of its production
UA97502C2 (ru) Кристаллическая твердая основа разагилина
IL195341A0 (en) Methods and materials for making simvastatin and related compounds
MX2007002470A (es) Fenilaminotiazoles sustituidos y su uso.
TW200617019A (en) A process for the preparation of 7α-alkylated 19-norsteroids
MY147247A (en) Organic compounds and their uses
MX2009005631A (es) Sulfuro de zinc transparente que tiene alta area superficial especifica.
MXPA05013202A (es) Tableta de multiples capas oralmente dispersable.
WO2007001962A3 (en) Systems and methods for generating biological material
TW200732410A (en) Sprayable acoustic compositions
NZ579478A (en) Epha3 antibodies for the treatment of solid tumors
WO2007109799A3 (en) Polymorphs of eszopiclone malate
PL1704047T3 (pl) Wielowarstwowe arkusze polimerowe
TW200643987A (en) Dielectric body and method for producing the same
UA103153C2 (ru) Core-1-положительный микроорганизм или его фракции для активирования клеточного иммунитета
TW200716561A (en) P38 inhibitors and methods of use thereof
MY149864A (en) Flavouring-containing pharmaceutical formulations with improved pharmaceutical properties